Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-27
2007-02-27
Chism, B. Dell (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S350000
Reexamination Certificate
active
10789548
ABSTRACT:
The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.
REFERENCES:
patent: 5906974 (1999-05-01), Blue et al.
patent: WO 88/01163 (1988-02-01), None
Lindberg et al. 1988, Lysine Vasopressin (LV) In The Treatment Of Refractory Hemodialysis Induced Hypotension (HIH), Kidney International, vol. 33, No. 1, p. 229.
Lindberg et al. Kindey International, 1988, vol. 33, No. 1, p. 229.
Dagher et al. Aliment Pharmacol. Ther., 2000, vol. 14. pp. 515-521.
Jarcuska, P. et al., “Hemodialysis in Hepatorenal Syndrome Type 1 in Alcoholic Liver Cirrhosis Treated by Continual Terlipressin Infusion in Combination with Albumin Plasmaexpansion,”Journal of Hepatology, 2003, 38:194-5, Abstract #675 (Exhibit 75).
Lindberg, Jill S. et al., “Lysine Vasopression (LV) in the Treatment of Refractory Hemodialysis Induced Hypotension (HIH),”Kidney International, 1988, 33:229 (Exhibit 76).
Landry, Donald W. et al., “Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock,”Circulation, 1997, 95:1122-5 (Exhibit 71).
Lilley, John J. et al., “Adrenergic Regulation of Blood Pressure in Chronic Renal Failure,”The Journal of Clinical Investigation, 1976, 57:1190-200 (Exhibit 72).
Price, Michael R., “(Glyco-) protein antigens and peptide epitopes of tumours,”Tumour Immunobiology: A Practical Approach, 1993, G. Gallagher et al. (eds.), pp. 63-79 (Exhibit 73).
Aisenbrey, Gary A. et al., “Vascular Effects of Arginine Vasopressin during Fluid Deprivation in the Rat,”The Journal of Clinical Investigation, 1981, 67:961-8 (Exhibit 2).
Ardaillou, Raymond et al., “Secretion and Catabolism of Antidiuretic Hormone in Renal Failure,”Contributions to Nephrology, 1986, 50:46-53 (Exhibit 3).
Argent, Nicholas B. et al., “Metabolic clearance rate of arginine vasopressin in severe chronic renal failure,”Clinical Science, 1992, 83:583-7 (Exhibit 4).
Baldamus, C. A. et al., “Sympathetic and Hemodynamic Response to Volume Removal during Different Forms of Renal Replacement Therapy,”Nephron, 1982, 31:324-32 (Exhibit 5).
Benmansour, Mustapha et al., “Metabolic clearance rate of immunoreactive vasopressin in man,”European Journal of Clinical Investigation, 1982, 12:475-80 (Exhibit 6).
Blumberg, Alfred et al., “Extracellular Volume in Patients with Chronic Renal Disease Treated for Hypertension by Sodium Restriction,”The Lancet, 1967, 2:69-73 (Exhibit 7).
Caillens, Henri et al., “Relationship between Change in Volemia at Constant Osmolality and Plasma Antidiuretic Hormone,”Mineral and Electrolyte Metabolism, 1980, 4:161-71 (Exhibit 8).
Campese, Vito M. et al., “Mechanisms of autonomic nervous system dysfunction in uremia,”Kidney International, 1981, 20:246-53 (Exhibit 9).
Charra, Bernard et al., “Control of Hypertension and Prolonged Survival on Maintenance Hemodialysis,”Nephron, 1983, 33:96-9 (Exhibit 10).
Converse, Jr., Richard L. et al., “Paradoxical Withdrawal of Reflex Vasoconstriction as a Cause of Hemodialysis-induced Hypotension,”The Journal of Clinical Investigation, 1992, 90:1657-65 (Exhibit 11).
D'Amore, T. Fasanella et al., “Response of plasma vasopressin to changes in extracellular volume and/or plasma osmolality in patients on maintenance hemodialysis,”Clinical Nephrology, 1985, 23:299-302 (Exhibit 12).
Daul, Anton E. et al., “Arterial hypotension in chronic hemodialyzed patients,”Kidney International, 1987, 32:728-35 (Exhibit 13).
Dunn, Fredrick L. et al., “The Role of Blood Osmolality and Volume in Regulating Vasopressin Secretion in the Rat,”The Journal of Clinical Investigation, 1973, 52:3212-9 (Exhibit 14).
Endou, Kyoko et al., “Hemodynamic Changes during Hemodialysis,”Cardiology, 1978, 63:175-87 (Exhibit 15).
Ewing, D. J. and R. Winney, “Autonomic Function in Patients with Chronic Renal Failure on Intermittent Haemodialysis,”Nephron, 1975, 15:424-9 (Exhibit 16).
Fisch, Bruce J. and David M. Spiegel, “Assessment of excess fluid distribution in chronic hemodialysis patients using bioimpedance spectroscopy,”Kidney International, 1996, 49:1105-9 (Exhibit 17).
Foley, Robert N. et al., “Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease,”Kidney International, 1996, 49:1379-85 (Exhibit 18).
Friess, U. et al., “Failure of arginine-vasopressin and other pressor hormones to increase in severe recurrent dialysis hypotension,”Nephrology Dialysis Transplantation, 1995, 10:1421-7 (Exhibit 19).
Graybiel, Ashton and R. Earle Glendy, “Circulatory Effects Following the Intravenous Administration of Pitressin in Normal Persons and in Patients with Hypertension and Angina Pectoris,”The American Heart Journal, 1941, 21:481-9 (Exhibit 20).
Grollman, Arthur and E. M. K. Geiling, “The Cardiovascular and Metabolic Reactions of Man to the Intramuscular Injection of Posterior Pituitary Liquid (Pituitrin), Pitressin and Pitocin,”The Journal of Pharmacology&Experimental Therapeutics, 1932, 46:447-60 (Exhibit 21).
Hegbrant, Jörgen et al., “Changes in Plasma Levels of Vasoactive Peptides during Standard Bicarbonate Hemodialysis,”Nephron, 1993, 63:303-8 (Exhibit 22).
Hegbrant, Jörgen et al., “Changes in Plasma Levels of Vasoactive Peptides during Sequential Bicarbonate Hemodialysis,”Nephron, 1993, 63:309-13 (Exhibit 23).
Heintz, B. et al., “Response of vasoactive substances to reduction of blood volume during hemodialysis in hypotensive patients,”Clinical Nephrology, 1993, 39:198-204 (Exhibit 24).
Heintz, B. et al., “Response of Vasoactive Substances to Intermittent Ultrafiltration in Normotensive Hemodialysis Patients,”Nephron, 1993, 65:266-72 (Exhibit 25).
Henderson, Lee W., “Symptomatic hypotension during hemodialysis,”Kidney International, 1980, 17:571-6 (Exhibit 26).
Henrich, William L. et al., “Role of osmolality in blood pressure stability after dialysis and ultrafiltration,”Kidney International, 1980, 18:480-8 (Exhibit 27).
Henrich, William L., “Hemodynamic instability during hemodiaylsis,”Kidney International, 1986, 30:605-12 (Exhibit 28).
Horký, K. et al., “Plasma Concentration of Antidiuretic Hormone in Patients with Chronic Renal Insufficiency on Maintenance Dialysis,”Hormone and Metabolic Research, 1979, 11:241-6 (Exhibit 29).
Iitake, Kazuhiro et al., “Effect of haemodialysis on plasma ADH levels, plasma renin activity and plasma aldosterone levels in patients with end-stage renal disease,”Acta Endocrinologica, 1985, 110:207-13 (Exhibit 30).
Jaeger, Jack Q. and Ravindra L. Mehta, “Assessment of Dry Weight in Hemodialysis: An Overview,”Journal of American Society of Nephrology, 1999, 10:392-403 (Exhibit 31).
Jawadi, M. Husain et al., “Regulation of Plasma Arginine Vasopressin in Patients with Chronic Renal Failure Maintained on Hemodialysis,”American Journal of Nephrology, 1986, 6:175-81 (Exhibit 32).
Kaliszan, R. et al., “Constrictory Activity of Three New Arginine-Vasopressin (AVP) Analogues (ALA-AVP, SER-ALA-AVP, THR-SER-ALA-AVP) Towards Isolated Rat Tail Artery as Related to AVP Alone,”Pharmacological Research Communications, 1988, 20:377-81 (Exhibit 33).
Katzarski, Krassimir S. et al., “A Critical Evaluation of Ultrasound Measurement of Inferior Vena Cava Diameter in Assessing Dry Weight in Normotensive and Hypertensive Hemodialysis Patients,”American Journal of Kidney Diseases, 1997, 30:459-65 (Exhibit 34).
Kaufmann, Horacio et al., “Plasma endothelin during upright tilt: relevance for orthostatic hypotension?”The Lancet, 1991, 338:1542-5 (Exhibit 35).
Kersh, Edward S. et
Landry Donald W.
Oliver Juan A.
Chism B. Dell
Intradialytic Pharmaceuticals
Mandel & Adriano
LandOfFree
Method for stabilizing blood pressure in hemodialysis subjects does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for stabilizing blood pressure in hemodialysis subjects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for stabilizing blood pressure in hemodialysis subjects will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3868124